Evidence map›Paper›PMID 34539893›Full record

ArticleJournal of Cancer2021

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy.

Yanjuan He, Duanfeng Jiang, Kaixuan Zhang, Yinghong Zhu, Jingyu Zhang, Xuan Wu, Jiliang Xia, Yan Zhu, Lang Zou, Jian Hu and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06709885 (HDAC Inhibitor Combination With Immunochemotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06709885 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

HDAC Inhibitor Combination With Immunochemotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: A Multicenter, Double-arm, Phase II Randomized Controlled Study

TypeinterventionalSponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityRan2024 to 2027Enrolled100ConditionsColon AdenocarcinomaArmsChidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yanjuan HeDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Duanfeng JiangDepartment of Hematology, The 3rd Xiangya Hospital, Central South University, Changsha, China.
Kaixuan ZhangDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yinghong ZhuCancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, China.
Jingyu ZhangCancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, China.
Xuan WuCancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, China.
Jiliang XiaCancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, China.
Yan ZhuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lang ZouDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jian HuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yajuan CuiDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, China.
Wen ZhouCancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha, China.
Fangping ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance is the major cause for disease relapse and patient death in multiple myeloma (MM). It is an urgent need to develop new therapies to overcome drug resistance in MM. Chidamide (CHI), a novel oral HDAC inhibitor targeting HDAC1, 2, 3 and 10, has shown potential therapeutic effect in MM. In this study, we determined that CHI exhibited significant anti-tumor effect on MM cells both

Indexed as

BortezomibChidamideMultiple myelomaReactive oxygen species

Identifiers

PMID34539893
PMCPMC8425211
OpenAlexW3198378665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.